Welcome to our dedicated page for Bergenbio As news (Ticker: BRRGF), a resource for investors and traders seeking the latest updates and insights on Bergenbio As stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bergenbio As's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bergenbio As's position in the market.
BerGenBio ASA (OSE: BGBIO) has appointed Olav Hellebø as CEO, effective November 21, 2024. Hellebø brings 30 years of pharmaceutical and biotechnology industry experience, including roles at Cytovation ASA, Antev , ReNeuron Group PLC, and Clavis Pharma ASA. He has also held leadership positions at UCB-Celltech, Novartis UK, and Schering-Plough. The company is developing selective AXL kinase inhibitors, with its candidate drug bemcentinib in clinical trials for non-squamous non-small cell lung cancer patients with STK11 gene mutations.
BerGenBio ASA has announced updated preliminary survival data from its ongoing Phase II study of bemcentinib in combination with low dose cytarabine for elderly patients with relapsed Acute Myeloid Leukaemia (AML). The study included an expansion cohort of 27 patients, showing a 31% overall response rate and a median overall survival of 13.3 months. Notably, patients receiving multiple cycles exhibited a 36% complete response rate. Ongoing discussions with FDA and EMA focus on a pivotal trial pathway for this combination therapy.
